Exhaled 8-isoprostane in childhood asthma

Respiratory Research

Peter J Barnes¹  Andrew Bush²  Nicola M Wilson²  Sergei A Kharitonov¹  Sukhbir K Shahid¹ 

[1] Section of Airway Disease, National Heart and Lung Institute, Imperial College London, London, UK;Department of Paediatrics, Royal Brompton Hospital, London, UK

关键词: childhood asthma;    exhaled breath condensate;    8-isoprostane;    oxidative stress;   

Others  :  1227266
DOI  :  10.1186/1465-9921-6-79

 received in 2005-02-21, accepted in 2005-07-21,  发布年份 2005

【 摘 要 】

Background

Exhaled breath condensate (EBC) is a non-invasive method to assess airway inflammation and oxidative stress and may be useful in the assessment of childhood asthma.

Methods

Exhaled 8-isoprostane, a stable marker of oxidative stress, was measured in EBC, in children (5–17 years) with asthma (13 steroid-naïve and 12 inhaled steroid-treated) and 11 healthy control.

Results

Mean exhaled 8-isoprostane concentration was significantly elevated in steroid-naïve asthmatic children compared to healthy children 9.3 (SEM 1.7) vs. 3.8 (0.6) pg/ml, p < 0.01. Children on inhaled steroids also had significantly higher 8-isoprostane levels than those of normal subjects 6.7 (0.7) vs. 3.8 (0.6) pg/ml, p < 0.01. Steroid-naïve asthmatics had higher exhaled nitric oxide (eNO) than those of controls 28.5 (4.7) vs. 12.6 (1.5) ppb, p < 0.01. eNO in steroid-treated asthmatics was similar to control subjects 27.5(8.8) vs. 12.6(1.5) ppb. Exhaled 8-isoprostane did not correlate with duration of asthma, dose of inhaled steroids or eNO.

Conclusion

We conclude that 8-isoprostane is elevated in asthmatic children, indicating increased oxidative stress, and that this does not appear to be normalized by inhaled steroid therapy. This suggests that 8-isoprostane is a useful non-invasive measurement of oxidative stress in children and that antioxidant therapy may be useful in the future.

【 授权许可】

   
2005 Shahid et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]van Den Toorn LM, Prins JB, de Jongste JC, Leman K, Mulder PG, Hoogsteden HC, Overbeek SE: Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. Respir Med 2005, 99:779-787.
• [2]Kharitonov SA, Barnes PJ: Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001, 163:1693-1722.
• [3]Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ: Reproducibility, reliability and diurnal variation of standardised exhaled NO measurements with NIOX™ in healthy and asthmatic children and adults made in routine clinical practice. Eur Respir J 2001, 18:4s.
• [4]Montuschi P, Corradi M, Ciabattoni G, Nightingale JA, Kharitonov SA, Barnes PJ: Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999, 160:216-220.
• [5]Hanazawa T, Kharitonov SA, Barnes PJ: Increased Nitrotyrosine in Exhaled Breath Condensate of Patients with Asthma. Am J Respir Crit Care Med 2000, 162:1273-1276.
• [6]Andreadis AA, Hazen SL, Comhair SA, Erzurum SC: Oxidative and nitrosative events in asthma. Free Radic Biol Med 2003, 35:213-225.
• [7]Morrow JD, Roberts LJ: The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997, 36:1-21.
• [8]Warner JO, Pohunek P, Marguet C, Roche WR, Clough JB: Issues in understanding childhood asthma. J Allergy Clin Immunol 2000, 105:S473-S476.
• [9]Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ: Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003, 21:433-438.
• [10]Montuschi P, Barnes PJ: Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci 2002, 23:232-237.
• [11]Montuschi P, Barnes PJ, Roberts LJ: Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004, 18:1791-1800.
• [12]Kharitonov SA, Logan-Sinclair RB, Busset CM, Shinebourne EA: Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. British Heart J 1994, 72:243-245.
• [13]Comhair SA, Ricci KS, Arroliga M, Lara AR, Dweik RA, Song W, Hazen SL, Bleecker ER, Busse WW, Chung KF, Gaston B, Hastie A, Hew M, Jarjour N, Moore W, Peters S, Teague WG, Wenzel SE, Erzurum SC: Correlation of Systemic Superoxide Dismutase Deficiency to Airflow Obstruction in Asthma. Am J Respir Crit Care Med 2005.
• [14]Montuschi P, Nightingale JA, Kharitonov SA, Barnes PJ: Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. Free Radic Biol Med 2002, 33:1403-1408.
• [15]Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax 2002, 57:889-896.